Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-22T16:10:20.975Z Has data issue: false hasContentIssue false
  • English
  • Français

The clinical use of milnacipran for depression

Published online by Cambridge University Press:  16 April 2020

Shigeru Morishita  and
Seizaburo Arita
Shigeru Morishita*
Affiliation:
Department of Psychiatry, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, 701-0192Okayama, Japan
Seizaburo Arita
Affiliation:
Department of Mathematics, Kansai Medical School, Hirakata, Osaka, Japan
*
*E-mail address: [email protected]
Get access

Abstract

We examined the relation between dosage and efficacy, and the predictors of response to milnacipran. There was no difference between 50 and 100 mg dose. However, the 100 mg dose had a faster onset of action than the 50 mg dose. An age and an episode have been predictors of milnacipran.

Keywords

MilnacipranAntidepressantDepressionPredictorOnset of actionDose
Type
Case report
Information
European Psychiatry , Volume 18 , Issue 1 , February 2003 , pp. 34 - 35
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Hordern, A, Burt, CG, Holt, NFDepressive states: a pharmacothera-peutic study. Springfield, IL: Charles C Thomas; 1965 pp. 70–97.Google Scholar
Lecrubier, Y, Pletan, Y, Solles, A, Tournoux, A, Magne, VClinical efficacy of milnacipran: placebo-controlled trial. Int Clin Psychophar-macol 1996;11(Suppl 4):29–33.CrossRefGoogle Scholar
Spencer, CM, Wilde, MI. Milnacipran: a review of its use in depression. Drug 1998;56:405–27.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.